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Factor XII (FXII), a clotting enzyme that can initiate coagulation in vitro, has 
long been considered dispensable for normal blood clotting in vivo because 
hereditary defi  ciencies in FXII are not associated with spontaneous or exces-
sive bleeding. However, new studies show that mice lacking FXII are protected 
against arterial thrombosis (obstructive clot formation) and stroke. Thus, FXII 
could be a unique drug target that could be blocked to prevent thrombosis 
without the side effect of increased bleeding.
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Hemostasis and thrombosis
The hemostatic system has evolved to 
maintain blood in a fl   uid state under 
physiological conditions, but also to react 
rapidly to vessel injury by sealing defects 
with fi  brin clots. Thrombosis, the pri-
mary cause of heart attacks and strokes, 
is thought to occur when natural anti  -
coagulant mechanisms, which help re-
strict the clot to the site of injury, are 
genetically impaired or are overwhelmed 
by the severity of the initial injury.
Platelets are critical for hemostasis 
both for the formation of blood clots, as 
platelet aggregates are an essential con-
stituent of the arterial thrombus, and as 
a platform for activation of coagulation 
proteins. However, this commentary 
will focus predominantly on the coagu-
lation system—a network of sequen-
tially activated plasma serine proteases 
that trigger the production of fi  brin, 
the protein that forms the meshwork 
of the clot. Normal blood clotting and 
thrombosis are thought to occur by the 
same pathway. In this issue, however, 
Kleinschnitz et al. (p. 513) show that 
FXII is required for thrombosis but is 
dispensable for normal clotting (1), sug-
gesting that the mechanisms regulating 
these two processes are not identical.
The clotting cascade
In the current view of physiological 
blood coagulation, the formation of 
fi  brin can be initiated through either of 
two converging cascades: the extrin-
sic pathway and the intrinsic pathway 
(Fig. 1). The extrinsic pathway is triggered 
when circulating factor VII (FVII) 
binds to its membrane-bound recep-
tor tissue factor (TF). TF is expressed 
on subendothelial layers of blood ves-
sels and on extravascular cells and thus 
is only exposed to the blood when the 
normal vasculature is disrupted (2). 
Once bound to TF, FVII is autoacti-
vated to form FVIIa. The FVIIa–TF 
complex then cleaves factor X (FX) 
into its active form (FXa). FXa is a key 
enzyme common to both the extrinsic 
and intrinsic coagulation pathways. FXa 
associates with factor V (FV) to form 
prothrombinase, which converts pro-
thrombin to thrombin. Thrombin in 
turn cleaves fi  brinogen to form fi  brin, 
thereby initiating the clot.
The intrinsic pathway is triggered 
by the activation of factor IX (FIX), 
which is mediated by the TF–VIIa com-
plex (3). Factor XI (FXI), a clotting 
factor upstream of FIX that is expressed 
on activated platelets, can be directly 
activated by thrombin and thus feeds 
into the intrinsic pathway (4). FXI then 
activates FIX to FIXa, which in turn 
activates FX in the presence of factor 
VIII (FVIII). The end result is a burst in 
the production of thrombin and the 
promotion of clot formation.
Hereditary defi  ciencies in proteins 
of the extrinsic pathway (FVII), the in-
trinsic pathway (FXI, FIX, FVIII), or 
proteins common to both pathways 
(FX, FV, prothrombin) impair blood 
clotting in vivo and lead to hemorrhagic 
disorders, thus demonstrating that both 
the extrinsic and intrinsic pathways of 
coagulation are essential for hemostasis.
Protective effects of FXII defi  ciency
The intrinsic pathway can also be acti-
vated in vitro by the autoactivation of 
FXII, for which the primary substrate 
is FXI. However, defi  ciencies in FXII 
do not cause abnormal or spontaneous 
bleeding in humans. Thus, FXII, which 
has been studied for over 50 years, was 
long considered dispensable for clotting 
in vivo. But two new studies now chal-
lenge this assumption (5). In a recent 
issue, Renne et al. showed that FXII-
  defi  cient mice, like humans, have normal 
hemostasis and no bleeding abnor-
malities. However, these mice failed 
to develop thrombosis in response to 
vessel injury. Administration of hu-
man FXII reversed the protective eff  ect, 
rapidly inducing thrombus formation. 
Based on these results, the authors con-
cluded that FXII is required only for 
pathologic coagulation and not for 
  hemostasis (5). In this issue, a report from 
the same group strengthens this hypo-
thesis. Kleinschnitz et al. (1) demonstrate 
that mice lacking FXII, or mice treated 
with a small molecule inhibitor of FXII, 
are protected against the development of 
ischemia-induced brain infarction (stroke) 
after cerebral artery occlusion (6). Again, 
the protection was specifi  cally caused 
by the FXII defi  ciency, as reconstituting 
the FXII-defi   cient mice with human 
FXII reversed the protective eff  ect. FXI-
defi  cient mice were also protected against 
stroke and both the FXI- and FXII-
defi   cient mice had reduced ischemia-
induced fi  brin accumulation in the brain 
compared with wild-type mice, suggest-
ing that the thrombosis-inducing eff  ects 
of FXII are mediated through FXI and 
the intrinsic pathway.
It is interesting to note that some 
people with hereditary defi  ciencies  in 
FXI, unlike those lacking FXII, suff  er 
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from mild bleeding disorders, suggesting 
that FXI is required for hemostasis and 
can be activated independently of FXIIa. 
As mentioned previously, thrombin can 
cleave and activate FXI (4), which can 
then convert FIX to FIXa in the coagula-
tion cascade (7). The ability of thrombin 
to activate FXI might explain why FXII 
is not required for physiological hemo-
stasis. But why FXII is strictly required 
for pathological coagulation is still not 
completely clear. Although these new 
data clearly demonstrate a requirement 
for the activation of FXI, FXII might 
act on other substrates that also play an 
  essential role in pathological thrombosis.
FXII could induce thrombosis via 
the extrinsic pathway
In thrombotic conditions, such as sepsis-
induced disseminated intravascular co-
agulation (DIC), bacterial endotoxin or 
proteoglycans may activate FXII. In addi-
tion, polyphosphates that are released upon 
platelet degranulation can also activate 
FXII, thus accelerating coagulation (8).
Activated FXII can cleave FVII to an 
activated form, which is identical to that 
produced by FXa in the extrinsic pathway. 
But unlike FXa, which eventually digests 
and inactivates the FVIIa that it produces, 
activated FXII produces a stable form of 
FVIIa (9). The availability of even a small 
concentration of FVIIa can markedly 
  accelerate the extrinsic pathway by two 
diff  erent mechanisms (Fig. 2). The fi  rst is 
through the normal autoactivation path-
way of FVII in the presence of exposed 
vascular TF, as occurs during physiologi-
cal blood clotting. The autoactivation of 
FVII requires a conformational change 
in FVIIa that occurs upon binding to TF. 
By cleaving FVII, FXIIa provides the ini-
tial few molecules of FVIIa that are needed 
to trigger for the exponential “explosion” 
of this autocatalytic cascade. The eff  ec-
tiveness of factor VIIa in triggering this 
cascade is evident in the successful use 
of recombinant FVIIa to treat bleeding 
episodes and during surgery in patients 
with hemophilia (10–12).
The second mechanism by which 
FXIIa-mediated activation of FVII 
can accelerate the extrinsic pathway 
is through interaction of FVII and TF 
that is exposed on activated circulating 
monocytes. One situation that triggers 
the cellular production of TF occurs dur-
ing heart bypass surgery. A progressive 
generation of thrombin during surgery is 
responsible for the thromboembolic and 
bleeding complications associated with 
these operations. During these proce-
dures, circulating monocytes become 
activated. Monocyte activation triggers 
an increase in the expression of integrins 
on the cell surface and the synthesis of 
TF (13, 14). Substantial concentrations 
of TF rapidly appear in the pericardial 
fl   uid during cardiopulmonary bypass 
surgery, and the production of TF is ac-
companied by thrombin formation (15). 
In the presence of TF, activated mono-
cytes convert all available FVII to FVIIa.
We have recently demonstrated a 
second mechanism by which soluble 
TF can generate FVIIa in the presence 
of FVII and activated monocytes (16). 
As the velocity of the reaction that 
produces FVIIa is proportional to the 
concentration of FVII available, the 
presence of additional FVIIa, such as that 
produced by FXIIa, would poten  tiate 
the extrinsic pathway. As mentioned 
previously, FXIIa can also activate FXI 
to FXIa on the surface of activated plate-
lets in the intrinsic pathway. Both FXIa 
and FVIIa–TF can convert FIX to FIXa. 
FIXa, in the presence of FVIII, activates 
FX—the convergence point in the ex-
trinsic and intrinsic pathways (Fig. 2). 
Activated monocytes and platelets are 
present during pathological thrombo-
sis (such as DIC), suggesting that these 
mechanisms most likely operate in a 
wide range of infl  ammatory conditions.
The contact system: an alternative 
thrombosis inducer?
Activated FXII (FXIIa) also triggers 
the production of vasoactive peptides 
known as kinins. This pathway—called 
the contact system—is triggered by the 
slow autoactivation of FXII (17) that oc-
curs when FXII is exposed to negatively 
charged surfaces such as the membranes 
of activated blood cells. FXIIa activates 
the serine protease kallikrein from its in-
active precursor prekallikrein. Kallikrein 
then activates FXII (thus amplifying the 
pathway) and also cleaves high molecular 
weight kininogen into the potent hypo-
tensive peptide bradykinin (18). Whether 
the contact system contributes to FXII-
driven thrombosis in models of stroke and 
arteriole injury is not yet known. How-
ever, previous work on another model 
of pathologic coagulation, DIC, suggests 
that the contact system might not be in-
volved in the   hemostatic defect (19).
DIC is a syndrome in which thrombin 
is produced in excess of antithrombin and 
exerts its actions systemically rather than 
locally (20), resulting in the formation of 
Figure 1.  Physiological coagulation. The extrinsic pathway is initiated by the binding of FVII to 
TF which results in the autoactivation of FVII (FVIIa). The activation of this pathway ultimately leads 
to the formation of  thrombin, which feeds back to activate FXI on the surface of platelets. FXIa then 
triggers the intrinsic pathway generating more thrombin and accelerating fi  brin formation.COMMENTARY
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fi  brin thrombi in the   microvasculature. 
DIC occurs in humans with bacterial sep-
ticemia, a disorder that is often accompa-
nied by hypotensive shock. My group has 
shown that FXII is activated in these pa-
tients, suggesting that this factor might 
play a role in the development of hypo-
tension associated with septicemia-
induced DIC (21). In a baboon model of 
sepsis, a monoclonal antibody to FXII 
prevented the development of irreversible 
hypotension, likely caused by the inhibi-
tion of bradykinin release. However, the 
anti-FXII antibody had no impact on the 
development of DIC. Thus, the hypoten-
sion, but not the hemostatic abnormality, 
appeared to be related to FXII-dependent 
activation of the contact system. How-
ever, these results do not rule out a role of 
the contact system in pathologic coagu-
lation because the human FXII-specifi  c 
antibody only neutralized 60% of baboon 
FXII. Thus, the residual FXII may have 
been suffi   cient to support DIC in this 
model.   Future studies will be required to 
determine whether the contact pathway 
contributes to thrombus formation in 
other models of pathological coagulation.
Therapeutic implications
The selection of anticoagulant therapy—
whether for venous thrombembolism or 
arterial thrombosis (myocardial infarc-
tion or stroke)—is based on how well 
the drug inhibits thrombosis and on the 
extent of the bleeding side eff  ects. The 
discovery that FXII defi  ciency protects 
against thrombosis without causing spon-
taneous bleeding makes FXII a unique 
and ideal target for drug design. Carefully 
performed experimental studies followed 
by controlled prospective clinical trials are 
required to validate this new hypothesis.
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Figure 2.  Pathological thrombosis FXII is activated by exposure to negatively charged 
  molecules to factor XIIa (FXIIa). FXIIa then cleaves FXI to FXIa, thus triggering the intrinsic pathway. 
Factor XIIa also hydrolyzes FVII to FVIIa, which combines with TF on the surface of  activated mono-
cytes or vascular cells to initiate the extrinsic system. Both coagulation pathways are required for 
pathological thrombosis as occurs during stroke and disseminated intravascular coagulation.